# A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine

> **NCT00976391** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 586 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **BIOLOGICAL:** albiglutide + insulin glargine
- **DRUG:** insulin glargine + preprandial lispro insulin

## Key facts

- **NCT ID:** NCT00976391
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2011-10
- **Final completion:** 2012-05
- **Target enrollment:** 586 (ACTUAL)
- **Last updated:** 2017-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00976391

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00976391, "A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00976391. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*